Mutant  Prevention  Concentration  Siprofloksasin Terhadap Escherichia coli Patogen dari Kloaka Broiler Secara In Vitro

Maria Fatima Palupi; Eli Nugraha; Meutia Hayati; Neneng Atikah

doi:10.22146/jsv.57040

Mutant Prevention Concentration Siprofloksasin Terhadap Escherichia coli Patogen dari Kloaka Broiler Secara In Vitro

https://doi.org/10.22146/jsv.57040

Maria Fatima Palupi^(1*), Eli Nugraha⁽²⁾, Meutia Hayati⁽³⁾, Neneng Atikah⁽⁴⁾

(1) Balai Besar Pengujian Mutu dan Sertifikasi Obat Hewan Kementerian Pertanian Republik Indonesia (National Veterinary Drug Assay Laboratory - Ministry of Agriculture Republic of Indonesia)
(2) Balai Besar Pengujian Mutu dan Sertifikasi Obat Hewan Kementerian Pertanian Republik Indonesia (National Veterinary Drug Assay Laboratory - Ministry of Agriculture Republic of Indonesia)
(3) Balai Besar Pengujian Mutu dan Sertifikasi Obat Hewan Kementerian Pertanian Republik Indonesia (National Veterinary Drug Assay Laboratory - Ministry of Agriculture Republic of Indonesia)
(4) Balai Besar Pengujian Mutu dan Sertifikasi Obat Hewan Kementerian Pertanian Republik Indonesia (National Veterinary Drug Assay Laboratory - Ministry of Agriculture Republic of Indonesia)
(*) Corresponding Author

Abstract

Mutant prevention concentration (MPC) is an in vitro test used to determine the lowest drug concentration needed to inhibit the growth of a single-step-mutant bacterial subpopulation. The purpose of this study was to determine the MPC value of ciprofloxacin against pathogenic Escherichia coli to obtained the range of mutant selection windows (MSW) of ciprofloxacin. Ciprofloxacin is a quinolone group that is included in the Highest Priority Critically Important Antimicrobials for Human Medicine but is also used for the treatment of bacterial infections in production animals. Twenty-four of pathogenic E. coli isolates sensitive to ciprofloxacin were tested to obtain MPC values and minimum inhibitory concentration (MIC) values. Test the MPC and MIC values to get the MSW range is done by the method of agar dilution. Mueller-Hinton agar containing standard ciprofloxacin was inoculated with 10¹⁰ cfu E. coli for the MPC test and 10⁴ for the MIC test. Based on the MPC test results, the MPC value of ciprofloxacin was 4-64 μg / mL (22.96 ± 19.07 μg / mL) and there was one isolate which had an MPC> 256 μg / mL. These results give a wide range of MSW with a lower limit of the MIC value of 0.25 - 2 µg / mL (0.55 ± 0.37 µg / mL) to the upper limit of the MPC value of 4-64 µg / mL (22.96 ± 19.07 μg / mL). Based on the results of this MPC assessment it can be concluded that the dose of ciprofloxacin in production animals has a wide range of MSW that is allow for single-step mutants.

Keywords

ciprofloxacin; E. coli; MPC; MSW

Full Text:

PDF

References

Ambarwati. (2014). Studi farmakokinetik siprofloksasin pada plasma, hati, ginjal, dan otot pada briler menggunakan kromatografi cair kinerja tinggi (KCKT). Fakultas Kedokteran Hewan Universitas Gadjah Mada, Yogyakarta Anadón, A., Martínez-Larrañaga, M.R., Iturbe, J., Martínez, M.A., Díaz, M.J., Frejo, M.T., Martínez, M. (2001). Pharmacokinetics and residues of ciprofloxacin and its metabolites in broiler chickens. Res Vet Sci. Oct;71(2):101-9. https://doi.org/10.1053/rvsc.2001.0494 Berkhoff, H.A. and Vinal, C.A. (1986). Congo red medium to distinguish between invasive and non-invasive Escherichia coli pathogenic for poultry. Avian Dis. 30(1):117-131. https://10.2307/1590621 Blondeau, J.M. (2009). New concepts in antimicrobial susceptibility testing: the mutant prevention concentration and mutant selection window approach. Vet Dermatol. (20):383-396. doi.org/10.1111/j.1365-3164.2009.00856.x Clinical Laboratory Standards Institute [CLSI]. (2016). M100S: Performance standards for antimicrobial susceptibility testing 26th Ed. CLSI. USA. pp: 52-54, 196 Cai, Y., Li, R., Liang, B., Bai, N., Liu, Y., Wang, R. (2010). In vitro antimicrobial activities and mutant prevention concentration of colistin against Acinetobacter baumannii. Antimicrob Agents Chemother. 54(9):3998-3999. doi:10.1128/AAC.00264-10 Choi, M.J. and Ko, K.S. 2014. Mutant prevention concentration of colistin for Acinetobacter baumanii, Pseudomonas aeroginosa and Klebsiella pneumonia clinical isolat. J Antimicrob Chemother. 69(1):275-277. doi.org/10.1093/jac/dkt315 Credito, K., Kosowska-Shick, K., Appelbaum, P.C. (2010). Mutant prevention concentration of four carbapenems against gram-negative rods. Antimicrob Agents Chemother. 54(6):2692-2695. doi:10.1128/AAC.00033-10 Daoud, Z., Sokhn, E.S., Azar, E., Masri, K., Doron, S. (2014). Mutant prevention concentration of ciprofloxacin against urinary isolates of Escherichia coli and Klebsiella pneumonia. J Infect Dev Ctries 8(2): 154-159. doi:10.3855/jidc.3164 Direktorat Jenderal Peternakan dan Kesehatan Hewan [DJPKH]. (2016). Indeks Obat Hewan Indonesia Ed. IX. Jakarta (ID): Kementerian Pertanian Republik Indonesia. pp. 58–599. Direktorat Jenderal Peternakan dan Kesehatan Hewan [DJPKH]. (2019). Surveilans resistensi antimikroba di sektor peternakan dan kesehatan hewan. Disampaikan oleh Direktorat Kesehatan Masyarakat Veteriner pada pertemuan pelarangan penggunaan kolistin pada tanggal 05 Desember 2019 di Kementerian Pertanian Drlica, K. (2003). The mutant selection window and antimicrobial resistance. J Antimicrob Chemother. August: 1-7.DOI: 10.1093/jac/dkg269 European Medicine Agency [EMA]. (2018). Guideline on the assessment of the risk to public health from antimicrobial resistance due to the use of an antimicrobial veterinary medicinal product in food producing animals (Draft 2). Retrieved Oktober 01, 2018 from www.ema.europa.eu/docs/en_gb/document_library/scientific_guideline/2018/07/WC500252679.pdf Gebru, E., Choi, M.J., Lee S.J., Damte, D., Park, S.C. (2011). Mutant prevention concentration and mechanism of resistance in clinical isolat and enrofloxacin/ marbofloxacin-selected mutants of Escherichia coli of canine origin. J Med Microbiol. 60(Pt10):1512-1522. doi:10.1099/JMM.0.028654-0 Gianvecchio, C., Lozano, N.A., Henderson, C., Kalhori, P., Bullivant, A., Valencia, A., Su, L., Bello, G., Wong, M., Cook, E., Fuller, L., Neal III, J.B., Yeh, P.J. (2019). Variation in mutant prevention concentration. Front Microbiol. 10:42. doi:10.3389/fmicb.2019.00042 Hansen, G.T, Zhao, X., Drlica, K., Blondeau, JM. (2006). Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa. Int J Antimicob Agents 27: 120-124 Hindler, J.A, and Humphries, R.M. (2013). Colistin MIC variability by method contemporary clinical isolates of multidrug-resistant gram negative bacilli. JCM. 51(6):1676-1684. doi:10.1128/JCM.03385-12 Ivanova, S., Dimitrova, D., Petrichev, M. (2017). Pharmacokinetics of ciprofloxacin in broiler chickens after single intravenous and intraingluvial administration. Mac Vet Rev 40 (1): 67-72 Khan, G.J., Khan, R.A., Majeed, I., Siddiqui, F.A., Khan, S. (2015). Ciprofloxacin; the frequent use in poultry and its consequences on human health. Professional Med J 22(1):001-005. Marcusson, L.L., Olofsson, S.K., Lindgren, P.K., Cars, O., Hughes, D. (2005). Mutant prevention concentration of ciprofloxacin for urinary tract infection isolates Escherichia coli.J Antimicrob Chemother. 55:938-943. doi:10.1093/jac/dki136 Mouton, J.W., Dudley, M.N., Cars, O., Derendorf, H., Drusano, G.L. (2005). Standardization of pharmacokinetic/ pharmacodinamis (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother. 55:601-607. doi.org/10.1093/jac/dki079 Randall, L.P, Cooles, S.W., Piddock, L.V.J, Woodward, M.J. (2004). Mutant Prevention concentration of ciprofloxacin for Salmonella enterica. J Antimicrob Chemother. 54: 688-691 World Health Organization [WHO]. (2017). Critically important antimicrobials for human medicine – 5th rev. WHO. Switzerland. Licence: CC BY-NC-SA 3.0 IGO. Pp:12-37

DOI: https://doi.org/10.22146/jsv.57040